GSDMC and neoplasm: Gsdmc-WT expression led to long-term rejection of 4TO7-Brca–KO tumors in immunocompetent mice treated with PARPi, with tumors taking an average of 120.5 days to regrow to 100 mm3 after tumor clearance (Figure 2I), indicating sustained antitumor immunity.